Tezacaftor/Ivacaftor

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTezacaftor/Ivacaftor
Drug Alias NameTezacaftor/ivacaftor and ivacaftorTezacaftor/ivacaftorVX-661/ivacaftorIvacaftor/VX 661PrSYMDEKO +[9] 
ClassificationSmall molecules
Mechanisms of ActionP-glycoprotein 1 inhibitorsCystic fibrosis transmembrane conductance regulator stimulants
TargetsCystic fibrosis transmembrane conductance regulatorP-glycoprotein 1
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsCystic Fibrosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/02/12
Country/TerritoryBelgiumCanadaUnited States +[17] 
CombinationsYes TezacaftorIvacaftor
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesVertex Pharmaceuticals Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesVertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (Ireland) Ltd
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeR07AX31
Related LinksN/A